Prestige Biopharma IDC Publishes Preclinical Efficacy Results of IDC007 in International Academic Journal

Prestige Biopharma IDC, the Korean subsidiary of Prestige Biopharma, announced on July 16 that the results of a preclinical efficacy evaluation of IDC007, its investigational treatment candidate for cytokine release syndrome (CRS), were published on July 10 in the international academic journal Frontiers in Immunology.

As cancer therapies that activate immune cells, including cell-based therapies, have become more widely used, demand has rapidly increased for treatments that can quickly control CRS, a major adverse effect of such therapies. Severe CRS can be life-threatening and may lead to the discontinuation of treatment, making alternative therapies essential for patients who do not respond to existing treatments or whose conditions deteriorate rapidly.

IDC007, featured in the journal article, is a bispecific antibody that simultaneously controls TNF-α, which is involved in the initial inflammatory response, and the IL-6 receptor (IL-6R), which amplifies systemic inflammation. It was designed to overcome the limitations of existing treatments that block only a single signaling pathway and to suppress the onset and progression of CRS through multiple mechanisms.

Through cellular and animal model studies, the researchers demonstrated that IDC007 effectively protected against not only CRS-inducing immune responses but also organ and vascular damage. In a humanized CRS mouse model, IDC007 achieved a 100% survival rate even when administered two hours after symptom induction, rather than as a preventive treatment before symptoms appeared, confirming its potential for practical therapeutic intervention.

Kim Na-ri, head of the Precision Antibody Group at Prestige Biopharma IDC, said, “This study demonstrated that IDC007’s multi-target blocking mechanism is effective in managing severe CRS. Based on the successful results of therapeutic administration after symptom onset, we will accelerate its development as an innovative new drug.”

Meanwhile, Prestige Biopharma IDC, located in Busan, is strengthening its research and development capabilities by carrying out the entire new drug development process, from the discovery of novel targets to candidate development and preclinical research.

Source: Consumer Times (https://www.cstimes.com/news/articleView.html?idxno=713670)